Skip to main content
SpringerLink
Log in

Chemotherapy of Liver Cancer

  • Chapter
Liver Cancer

Part of the book series: Developments in Oncology ((DION,volume 30))

Abstract

The chemotherapy of primary and secondary neoplasms of the liver has evolved over the past decades passing through phases of single-agent systemic treatment; regional infusion chemotherapy; combination or multidrug chemotherapy; and finally, the present resurgence of regional delivery systems with single or multiple agents. The chemotherapeutic agents employed as a common denominator throughout the chronology of liver tumor therapy have been the fluoropyrimidines which exist as the inadequate “standard” for the palliative treatment of gastrointestinal malignancies. It would be fair to state at the outset that the systemic chemotherapy for primary and secondary tumors of the liver is woefully inadequate, and existing regimens do not consistently yield objective tumor responses of more than 20% or demonstrate a meaningful impact on survival. The exceptions to this perspective are the clinical circumstances in which the liver is occupied by responsive tumors such as breast cancer or lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chau KT. The management of primary liver carcinoma. Ann R Coll Surg Eng 41:253, 1971.

    Google Scholar 

  2. Link JS, Bateman JR, Paroly WS, Durkin WJ, Peters RL. 5-Fluorouracil in hepatocellular carcinoma: report of twenty-one cases. Cancer 39(5): 1936–1939, 1977.

    Article  PubMed  CAS  Google Scholar 

  3. Geddes EW, Falkson G. Malignant hepatoma in the Bantu. Cancer 25:1271–1278, 1970.

    Article  PubMed  CAS  Google Scholar 

  4. Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42:2149–2156, 1978.

    Article  PubMed  CAS  Google Scholar 

  5. Olweny CLM, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H. Treatment of hepatocellular carcinoma with adriamycin: preliminary communication. Cancer 36:1250–1257, 1975.

    Article  PubMed  CAS  Google Scholar 

  6. Vogel CL, Bayley AC, Brooker RJ, Anthony PP, Ziegler JL. A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 39:1923–1929, 1977.

    Article  PubMed  CAS  Google Scholar 

  7. Ihde DC, Kane RC, Cohen MH, Mclntire KR, Minna JD. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep 61 (7):1385–1387, 1977.

    PubMed  CAS  Google Scholar 

  8. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma: a comparison of VP-16 with adriamycin. Cancer 51:206–210, 1983.

    Article  PubMed  CAS  Google Scholar 

  9. Plengvanit U, Viranuvatti V. Treatment of primary carcinoma of the liver with nitrogen mustard and prednisolone. Am J of Gastroenterology 42:521–528, 1964.

    CAS  Google Scholar 

  10. Tester WJ, Donehower RC, Eddy JL, Myers CE, Ihde DC. Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors. Cancer Chemother and Pharmacol 8:305–310, 1982.

    CAS  Google Scholar 

  11. Cavalli F, Rozencweig M. Renard J, Goldhirsch A, Hansen HH. Phase II study of oral VP-16–213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 17 (10): 1079–1082, 1981.

    Article  PubMed  CAS  Google Scholar 

  12. Kennedy PS, Lehane DE, Smith FE, Lane M. Oral fluorouracil therapy of hepatoma. Cancer 39:1930–1935, 1977.

    Article  PubMed  CAS  Google Scholar 

  13. Falkson G, VonHoff D, Klaassen D, DuPlessis H, VanDerMerwe CF, VanDerMerwe AM, Carbone PP. A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. Cancer Chemother and Pharmacol 4:33–36, 1980.

    CAS  Google Scholar 

  14. Melia WM, Westaby D, Williams R. Diaminodichloride platinum (cis-platinum) in treatment of hepatocellular carcinoma. Clin Oncol 7:275–280, 1981.

    PubMed  CAS  Google Scholar 

  15. Bukowski RM, Legha S, Saiki J, Eyre HJ, O’Bryan R. Phase II trail of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group study. Cancer Treat Rep 66(8):1651–1652, 1982.

    PubMed  CAS  Google Scholar 

  16. Cheng E, Lightdale C, Young C, Yagoda A. Fortner J, Golbey R. Phase II trial of (m-AMSA) 4′–9-(acridinylamino)-methanesulfon-m-aniside in primary liver cancer. Am J Clin Oncol (CCT) 6:211–213, 1983.

    Article  CAS  Google Scholar 

  17. Gailani S, Holland JF, Falkson G, et al. Comparison of treatment of metastatic gastrointestinal cancer with 5-FU to a combination of 5-FU with cytoxine arabinoside. Cancer 29:1308–1313, 1972.

    Article  PubMed  CAS  Google Scholar 

  18. Moertel CG. Clinical management of advanced gastric cancer. Cancer 36:675–682, 1975.

    Article  PubMed  CAS  Google Scholar 

  19. Baker LH, Saidi JH, Jones SE, Hewlett JS, Brownlee RW, Stephens RL, Vaitkevicius VK. Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study. Cancer Treat Rep 61(8):1595–1597, 1977.

    PubMed  CAS  Google Scholar 

  20. Olweny CLM, Katongole-Mbidde E, Bahendeka S. Otim D, Mugerwa J, Kyalwazi SK. Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer 46:2717–2722, 1980.

    Article  PubMed  CAS  Google Scholar 

  21. Chlebowski RT, Chang KK, Tong MJ, Weiner JM, Ryden VMJ, Bateman JR. Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. Cancer 48:1088–1095, 1981.

    Article  PubMed  CAS  Google Scholar 

  22. Lee YT. Systemic and regional treatment of primary carcinoma of the liver. Cancer Treat Reviews 4:195–212, 1977.

    Article  CAS  Google Scholar 

  23. Falkson G. Therapeutic approaches to hepatoma. Cancer Treat Rev 2:73–76, 1975.

    Article  PubMed  CAS  Google Scholar 

  24. Moertel C. Chemotherapy of gastrointestinal cancer. New Eng J Med 229:1049, 1978.

    Article  Google Scholar 

  25. Baker LH, Talley RW, Maiter R, et al. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU. Cancer 38:1, 1976.

    Article  PubMed  CAS  Google Scholar 

  26. Seifert P, Baker LH, Reed MD, et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123, 1975.

    Article  PubMed  CAS  Google Scholar 

  27. Grage TB, Vassilopoulos P, Shingleton WW, et al. Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil vs intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: a Central Oncology Group study. Surg 86:550–555, 1979.

    CAS  Google Scholar 

  28. Moertel CG, Schutt AL, Hahn GR, et al. Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1–2-cis(2-chlorethyl)–1 nitrosourea, and vincristine, brief communication. J Natl Cancer Inst 54:69, 1975.

    PubMed  CAS  Google Scholar 

  29. Buroker T, Kim PN, Groppe C, et al. 5-FU infusion with Methyl-CCNU in the treatment of advanced colon cancer. Cancer 42:1228, 1979.

    Article  Google Scholar 

  30. Kemeny N, Yagoda A, Golbey RB. A randomized study of two different schedules of Methyl-CCNU, 5-FU and vincristine for metastatic colorectal carcinoma. Cancer 43:78, 1979.

    Article  PubMed  CAS  Google Scholar 

  31. Kemeny N, Yagoda A, Braun D. Metastatic colorectal carcinoma: a prospective randomized trial of methyl-CCNU, 5-fluorouracil (5-FU) and vincristine (MOF) vs MOF plus streptozotocin (MOF-Strep). Cancer 51(1):20–24, 1983.

    Article  PubMed  CAS  Google Scholar 

  32. Lavin P, Mittelman A, Douglass H, Engstrom P, Klaassen D. Survival and response to chemotherapy for advanced colorectal adenocarcinoma: an Eastern Cooperative Oncology Group report. Cancer 46:1536–1543, 1980.

    Article  PubMed  CAS  Google Scholar 

  33. Kemeny N, Michaelson R. Phase II trial of low dose methotrexate and sequential 5-fluorouracil in the treatment of metastatic colorectal carcinoma. Proc. ASCO 23–85, 1982.

    Google Scholar 

  34. MacDonald JS, Schein PS, Woolley PV, et al. 5-fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Int Med 93:533–536, 1980.

    PubMed  CAS  Google Scholar 

  35. Moertel CG, Lavin PT. Phase II—III chemotherapy studies in advanced cancer. Cancer Treat Rep 63:1863, 1979.

    PubMed  CAS  Google Scholar 

  36. Kovach JS, Moertel CG, Schutt AJ, et al. A controlled study of combined 1, 3-bis-(2-chloro-ethyl)–1-nitrosourea and 5-fluorouracil therapy for advanced gastric, and pancreatic cancer. Cancer 33:563–567, 1974.

    Article  PubMed  CAS  Google Scholar 

  37. Smith FP, Hoth DF, Levin B, et al. 5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in the treatment of advanced pancreatic carcinoma. Cancer 46:2008–2013, 1980.

    Google Scholar 

  38. Hall SW, Benjamin RS, Murphy WK, Valdivieso M, Bodey GP. Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer. Cancer 44:2008–2013, 1979.

    Article  PubMed  CAS  Google Scholar 

  39. Perpetuo MDCMO, Valdivieso M, Heilburn LK, Nelson RS, Connor T, Bodey GP. Natural history study of gallbladder cancer: a review of 36 years experience at M.D. Anderson Hospital and Tumor Institute. Cancer 42:330–335, 1978.

    Article  PubMed  CAS  Google Scholar 

  40. Shieh CJ, Dunn E, Standard JE. Primary carcinoma of the gallbladder: a review of a 16-year experience at the Waterbury Hospital Health Center. Cancer 47:996–1004, 1981.

    Article  PubMed  CAS  Google Scholar 

  41. O’Connell MJ, O’Fallon J, Lavin PT, Bruckner HW, Douglass HO, Livstone EM, et al. A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma, the Gastrointestinal Tumor Study Group. Cancer 49 (7): 1362–1366, 1982.

    Article  Google Scholar 

  42. Schein PS, Lavin PT, Moertel CG, Kaiser M. Douglass HO, Lokich J, et al. Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measureable pancreatic carcinoma, a GITSG report. Cancer 42:19–22, 1978.

    Article  PubMed  CAS  Google Scholar 

  43. Kopelson G, Harisiadis L, Tretter P, Chang CH. The role of radiation therapy in cancer of the extra-hepatic biliary system: an analysis of thirteen patients and a review of the literature of the effectiveness of surgery, chemotherapy, and radiotherapy. Int J Radiation Oncology Biol Phys 2:883–894, 1977.

    Article  CAS  Google Scholar 

  44. Bruckner HW, Spigelman MK, Mandel E, Cohen C. Deppe G. Turell R, Schiavone H. Carcinoma of the anus treated with combination of radiotherapy and chemotherapy. Cancer Treat Rep 63(3):385–398, 1979.

    Google Scholar 

  45. Kelsen MP, Bains M. Chapman R, Golbey R. Cisplatin, vindesine, and bleomycin (DVB) combination chemotherapy for esophageal carcinoma. Cancer Treat Rep65:781–785, 1981.

    PubMed  CAS  Google Scholar 

  46. Fisher WB, Herbst KD, Sims JE, Critchfield CF. Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiamineplatinum (II). Cancer Treat Rep 62:91–97, 1978.

    PubMed  CAS  Google Scholar 

  47. Gisselbrech C, Calvo F, Mignot L, Pujade E, Bouvry M. Danne O, Belpomme D, Marty M. Fluorouracil (F), adriamycin (A), and cisplatin (P) (FAP): combination chemotherapy of advanced esophageal carcinoma. Cancer 52:974–977, 1983.

    Article  Google Scholar 

  48. Canellos GP, DeVita VT, Gold GL, et al. Combination chemotherapy for advanced breast cancer: response and effect on survival. Annals of Int Med 84:389–392, 1976.

    CAS  Google Scholar 

  49. Canellos GP, Stuart JP, Taylor SG, et al. Combination chemotherapy for metastatic breast carcinoma. Cancer 38:1882–1886, 1976.

    Article  PubMed  CAS  Google Scholar 

  50. Smalley RV, Carpenter J, Bartolucci A, et al. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A Southeastern Cancer Study Group project. Cancer 40:625–632, 1977.

    Article  PubMed  CAS  Google Scholar 

  51. Muss HB, White DR, Richards II F, et al. Adriamycin vs methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 42:2141–2148, 1978.

    Article  PubMed  CAS  Google Scholar 

  52. Russell JA, Baker JW, Dady PJ, et al. Combination chemotherapy of metastatic breast cancer with vincristine, adriamycin, and prednisolone. Cancer 41:396–399, 1978.

    Article  PubMed  CAS  Google Scholar 

  53. Chauvergne J, Bary-bobo J, Klein T, et al. Polychimiotherapie des cancers mammaires en phase avancée. Association ternaire avec doxorubicine analyse de 209 observations. Bulletin du Cancer 64(4):667–680, 1977.

    PubMed  CAS  Google Scholar 

  54. Jones SE, Durie BG, Salmon SE. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36:90–97, 1975.

    Article  PubMed  CAS  Google Scholar 

  55. Tranum B, Hoogstraten B, Kennedy A, et al. Adriamycin in combination for the treatment of breast cancer. Cancer 41:2078–2083, 1978.

    Article  PubMed  CAS  Google Scholar 

  56. Mattsson W, Arwidi A, vonEyben F, et al. Phase II study of combined vincristine, adriamycin, cyclophosphamide, and methotrexate with citrovorum factor rescue in metastatic breast cancer. Cancer Treat Rep 61:1527–1531, 1977.

    PubMed  CAS  Google Scholar 

  57. Johnson RO, Metter G, Wilson W, et al. Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. Cancer Treat Rep 60:183–187, 1976.

    PubMed  CAS  Google Scholar 

  58. Costanza ME, Nathanson L, Schoenfeld D, et al. Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40:1010–1015, 1977.

    Article  PubMed  CAS  Google Scholar 

  59. Pritchard KI, Quirt IC, Cowan DH, et al. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Cancer Treat Rep 64:1123–1126, 1980.

    PubMed  CAS  Google Scholar 

  60. Nathanson S, Kaufman SD, Carey RW. Vinblastine, infusion, bleomycin and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma. Cancer 48:1290–1294, 1981.

    Article  PubMed  CAS  Google Scholar 

  61. Beretta G, Bonadonna G, Cascinelli N, et al. Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study. Cancer Treat Rep 60:33–40, 1976.

    PubMed  CAS  Google Scholar 

  62. Metelski HW, Lokich JJ, Huberman MS, Zipoli TE, Paul S, Sonneborn H, Phillips D. Adriamycin, cyclophosphamide and etoposide (VP-16–213) in extensive stage small cell lung cancer. Amer Journal of Clin One (in press).

    Google Scholar 

  63. Gralle RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Int Med 95:414, 1981.

    Google Scholar 

  64. Bitran JD, Desser RK, DeMeester TR, et al. Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)—effective four-drug combination chemotherapy for metastatic non-out cell bronchogenic carcinoma. Cancer Treat Rep 60:1225–1237, 1976.

    PubMed  CAS  Google Scholar 

  65. Eagan RT, Frytak S, Creagan, ET, et al. Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 63:1589, 1979.

    PubMed  CAS  Google Scholar 

  66. Vogl SE, Mehta CR, Cohen MH. MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung. Low response rate in cooperative group study. Cancer 44:864–868, 1979.

    Article  PubMed  CAS  Google Scholar 

  67. Miller TP, McMahon LJ, Livingston RB. Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine and mitomycin-C (FOMi). Cancer Treat Rep 64:1241–1245, 1980.

    PubMed  CAS  Google Scholar 

  68. Lanzotti VJ, et al. Survival with inoperable lung cancer. An integration of prognostic variables based on clinical criteria. Cancer 39:303–313, 1977.

    Article  PubMed  CAS  Google Scholar 

  69. Moertel CG, Hanley JA, Johnson LA. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. New Eng J Med 303:1189–1194, 1980.

    Article  PubMed  CAS  Google Scholar 

  70. Kessinger A, Foley JF, Lemon, et al. DTIC therapy for malignant islet-cell tumors. Proc ASCO 1:169, 1982.

    Google Scholar 

  71. Legha SS, Valdivieso M, Nelson RS, et al. Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature. Cancer Treat Rep 61:1699–1703, 1977.

    PubMed  CAS  Google Scholar 

  72. Feldman JM, Quickel KE, Marecek RL, et al. Streptozotocin treatment of metastatic carcinoid tumors. South Med J 65:1325–1327, 1972.

    Article  PubMed  CAS  Google Scholar 

  73. Aisner J, et al. Doxorubicin, cyclophosphamide, and etoposide in the treatment of small cell lung cancer. Cancer Chemo and Pharmacol 7:187–193, 1982.

    CAS  Google Scholar 

  74. Haq MM, Legha SS. Samaan NA, Bodey GP, Burgess MA. Cytotoxic chemotherapy in adrenal cortical carcinoma. Cancer Treat Rep 64:909–913, 1980.

    PubMed  CAS  Google Scholar 

  75. Einhorn LH. Testicular cancer as a model for curable neoplasm: the Richard and Hinda Rosenthal Foundation Award lecture. Cancer Research 41:3275–3280, 1981.

    PubMed  CAS  Google Scholar 

  76. Katz ME, Schwartz PE, Kapp DS, Luikart S. Epithelial carcinoma of the ovary: current strategies. Annals of Int Med 95:98–111, 1981.

    CAS  Google Scholar 

  77. Kukhari A, Connors TA, Gilsenan AM, Ross WCJ, Tisdale MJ, Warwick GP, Wilman DEV. Cytotoxic agents designed to be selective for liver cancer. J. Natl Cancer Inst 50:243–247, 1973.

    Google Scholar 

  78. Lokich JJ, Kinsella T, Perri J, Malcolm A. Clouse M. Concomitant hepatic radiation and intra-arterial fluorinated pyrimidine therapy: Correlation of liver scan, liver function tests, and plasma CE A with tumor response. Cancer 48:2569–2574, 1981.

    Article  PubMed  CAS  Google Scholar 

  79. Lokich JJ: Hepatic artery chemotherapy: the relative importance of direct organ distribution vs the constant infusion schedule. Am J Clin Oncol: Cancer Clin Trials (in press).

    Google Scholar 

  80. Lokich JJ. Bothe A, Yanes L, Moore C. Continuous infusion chemotherapy with an ambulatory pump. Proceedings, 13th Internatl Congress of Chemotherapy, Vienna, Austria, August 1983.

    Google Scholar 

  81. Lokich JJ, Bothe A. Fine N, Perri J. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565–2568, 1981.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Jacob J. Lokich
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Rita and Stanley H. Kaplan Cancer Center, New York University Medical Center, 550 First Avenue, New York, NY, 10016, USA

    Joseph C. Bottino M.D.  & Franco M. Muggia M.D.  & 

  2. Clinical Oncology Program, University of California,Irvine Medical Center, Orange, CA, 92668, USA

    Richard W. Opfell M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishing, Boston/Dordrecht/Lancaster

About this chapter

Cite this chapter

Lokich, J.J. (1985). Chemotherapy of Liver Cancer. In: Bottino, J.C., Opfell, R.W., Muggia, F.M. (eds) Liver Cancer. Developments in Oncology, vol 30. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2593-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2593-2_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9625-6

  • Online ISBN: 978-1-4613-2593-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation